Immatics
tolerability profile all grade adverse events voe | Immatics
Company
Deck Type
Sector
Industry
Deck date
October 2022
Slide
22 of 25
Similar slides by Immatics
See diffirences between slides (animation)
Investor Presentation
November 2023
gen at tolerability data | Immatics
Investor Presentation
November 2023
tolerability data cohort gen | Immatics
Investor Presentation
November 2023
gen across all dose levels tolerability data | Immatics
Related slides by other companies
Nuvalent
Investor Presentation
February 2024
preliminary safety profile favorable and consistent with alk selective sparing design of phase treatment related adverse events in patients all treated patients has not been identified transient asymptomatic grade increase infrequent requiring dose modification discontinued due to dose reduced due to overall avoiding related any alt increased ast increased nausea constipation fatigue peripheral edema grade grade grade any grade resulting in treat resulting in dose reduced dose for source lin grade alt ast elevation grade nausea cognitive disturbance grade elevation grade treatment continues at the city treatment related adverse event at from | Nuvalent
Nuvalent
Investor Presentation
January 2024
preliminary safety profile favorable and consistent with alk selective sparing design of phase has not been identified transient asymptomatic grade increase treatment related adverse events in patients all treated patients grade grade grade any grade infrequent requiring dose any modification discontinued due to dose reduced due to overall avoiding related alt increased ast increased nausea constipation fatigue peripheral edema data cut off alt alanine ast aspartate creatinine dose limiting toxicity treatment related adverse event resulting in treatment discontinuation were grade alt grade ast elevations intolerable grade constipation occurred at following dose increase from resulting in dose reduction were grade alt ast elevation grade alt ast elevation grade nausea cognitive disturbance grade elevation grade treatment continues at the reduced dose for these patients source lin on | Nuvalent
Nuvalent
Investor Presentation
January 2024
preliminary safety profile favorable and consistent with alk selective sparing design of phase has not been identified transient asymptomatic grade increase treatment related adverse events in patients all treated patients grade grade grade any grade infrequent requiring dose any modification discontinued due to dose reduced due to overall avoiding related alt increased ast increased nausea constipation fatigue peripheral edema data cut off alt alanine ast aspartate creatinine dose limiting toxicity treatment related adverse event resulting in treatment discontinuation were grade alt grade ast elevations intolerable grade constipation occurred at following dose increase from resulting in dose reduction were grade alt ast elevation grade alt ast elevation grade nausea cognitive disturbance grade elevation grade treatment continues at the reduced dose for these patients source lin i | Nuvalent
Alkermes
Investor Presentation
October 2023
adverse event profile in artistry was consistent with our expectations based on its mechanism of action | Alkermes
Other recent decks by Immatics
See all presentations (2 decks)
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io